Drugs / XSTEM-VLU
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05549609 | Oct 2022 → Feb 2026 | ulcer of lower limbs | Xintela AB | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XSTEM-VLU | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05549609 ↗ |
| Modality | Cell therapy | “mesenchymal stem cell (MSC) product” NCT05549609 ↗ |
| Route | Topical | “administered as a single topical dose” NCT05549609 ↗ |